Blueprint Medicines Corporation (LON:0HOJ)
129.31
+0.02 (0.01%)
At close: Jul 11, 2025
Blueprint Medicines Employees
Blueprint Medicines had 649 employees as of December 31, 2024. The number of employees decreased by 6 or -0.92% compared to the previous year.
Employees
649
Change (1Y)
-6
Growth (1Y)
-0.92%
Revenue / Employee
635.15K GBP
Profits / Employee
-175.96K GBP
Market Cap
6.20B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,382 |
Blueprint Medicines News
- 22 days ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 26 days ago - Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
- 27 days ago - HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC) - Benzinga
- 27 days ago - HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC) - GlobeNewsWire
- 4 weeks ago - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - Benzinga
- 4 weeks ago - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PRNewsWire
- 5 weeks ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 5 weeks ago - This ASML Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga